Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirme

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $92.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 123.79% from the company’s previous close. […]

Related Keywords

Pascal Deschatelets , Robertw Baird , Timothy Eugene Sullivan , Polar Capital Holdings Plc , Apellis Pharmaceuticals Inc , Apellis Pharmaceuticals Stock Performance , Norges Bank , Vanguard Group Inc , Jefferies Financial Group , News Ratings For Apellis Pharmaceuticals Daily , Apellis Pharmaceuticals , Jpmorgan Chase Co , Securities Exchange Commission , Wells Fargo Company , Analyst Recommendations For Apellis Pharmaceuticals , Pricet Rowe Associates Inc , Get Free Report , Financial Group , Exchange Commission , Eugene Sullivan , Capital Holdings Plc , Apellis Pharmaceuticals Daily ,